Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study

•Real-world data on the treatment of 432 patients with extensive-stage SCLC in Germany.•93% of the patients received first-line platinum-based combination chemotherapy.•Carboplatin or cisplatin combinations yielded similar response and survival rates.•50% of the patients received a second and 22% a third line of treatment.•77% of the patients in routine care would be eligible for a clinical trial.